Compare AMBQ & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBQ | REPL |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2025 | 2018 |
| Metric | AMBQ | REPL |
|---|---|---|
| Price | $62.91 | $12.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $42.20 | $5.67 |
| AVG Volume (30 Days) | 374.6K | ★ 2.2M |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $72,514,000.00 | N/A |
| Revenue This Year | $41.81 | N/A |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.12 | $1.50 |
| 52 Week High | $91.61 | $16.33 |
| Indicator | AMBQ | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 42.98 |
| Support Level | $55.79 | $6.81 |
| Resistance Level | $68.15 | $16.02 |
| Average True Range (ATR) | 2.75 | 0.71 |
| MACD | 0.84 | -0.45 |
| Stochastic Oscillator | 59.61 | 14.89 |
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the power consumption challenges of general purpose and AI compute - especially at the edge. The company provides a full-stack solution encompassing tightly integrated hardware and software. Its solutions include a diverse family of systems-on-chip (SoCs) and the software required to enable on-chip AI processing, general compute, sensing, security, storage, wireless connectivity, and developed graphics.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.